Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies (15-02-2018)

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance ofHIV viral suppression in patients with high cardiovascular (01-02-2018)

IV Jornadas Docentes de GeSIDA

Fecha de inicio y cierre del curso:
Madrid  los días 28 y 29 de Septiembre  de 2018

Descargar Convocatoria
Descargar Formulario de Solicitud

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review andmeta-regression analysis (18-01-2018)

Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older (01-01-2018)

Estudio de la patología anal por VPH en personas con VIH

Presentaciones: Ver

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, noninferiority trial (15-12-2017)

Antiretroviral combination use during pregnancy and the risk of major congenital malformations (01-12-2017)

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study (16-11-2017)

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of randomised, open-label, phase 2b, non-inferiority trial (02-11-2017)